Gilead Sciences (GILD) is a publicly traded Healthcare sector company. As of November 17, 2026, GILD trades at $170.51 with a market cap of $208.48B and a P/E ratio of -55.34. GILD moved +2.01% today. Year to date, GILD is +37.80%; over the trailing twelve months it is +34.03%. Its 52-week range spans $93.37 to $176.58. Analyst consensus is strong buy with an average price target of $173.76. Rallies surfaces GILD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Gilead Sciences (GILD) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. GILD moved +2.01% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $170.51 |
| Market Cap | $208.48B |
| P/E Ratio | -55.34 |
| EPS | $-2.60 |
| Dividend Yield | 0.82% |
| 52-Week High | $176.58 |
| 52-Week Low | $93.37 |
| Volume | 2.80M |
| Avg Volume | 0 |
| Revenue (TTM) | $30.46B |
| Net Income | $-3.24B |
| Gross Margin | 79.59% |
23 analysts cover GILD: 0 strong buy, 18 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $173.76.